Regenerative Medicine (PDF)

Tingting Qiu holds a PhD degree in public health and a master's degree in pharmacology. Her area of expertise includes regulatory affairs, health policy, health technology assessment, economic analysis, and price and reimbursement of innovative therapies, such as orphan drugs and regenerative medicines. She has authored over 30 publications and conference presentations focused on the market access of cell and gene therapies at the European and global level. She worked as a price and market access analyst at Creativ-Ceutical (Paris, France) for 4 years from 2018, during which she was deeply involved in addressing the challenges in meeting the expectations of relevant stakeholders to facilitate the patient access to lifesaving treatments. Since 2021, she has been a research associate to EA 3279 CERESS Department of Public Health at Aix-Marseille University. Currently, she is a researcher in the Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University (Beijing, China). Apart from endeavoring to advance the market access of cell and gene therapies in China and globally, she is also engaged in projects focusing on the impact of implementing diagnosis-related groups reform on the healthcare system, the methodology of health economic analysis in China, and evidence-based assessment of Chinese and western medicines.

Mondher Toumi is an MD by training and has an MSc in biostatistics and in biological sciences (option pharmacology) and a PhD in economic sciences. Toumi is a professor of public health at Aix-Marseille University. After working for 12 years as research manager in the Department of Pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraced a career in the pharmaceutical industry for 13 years. Toumi was appointed global vice president at Lundbeck A/S in charge of health economics, outcome research, pricing, market access,